NasdaqGS:NUVA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. More Details


Snowflake Analysis

Fair value with moderate growth potential.


Similar Companies

Share Price & News

How has NuVasive's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NUVA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-9.8%

NUVA

-0.8%

US Medical Equipment

-1.5%

US Market


1 Year Return

-27.0%

NUVA

15.2%

US Medical Equipment

12.9%

US Market

Return vs Industry: NUVA underperformed the US Medical Equipment industry which returned 15.2% over the past year.

Return vs Market: NUVA underperformed the US Market which returned 12.9% over the past year.


Shareholder returns

NUVAIndustryMarket
7 Day-9.8%-0.8%-1.5%
30 Day-5.7%1.2%-1.8%
90 Day-9.8%10.8%6.6%
1 Year-27.0%-27.0%16.2%15.2%15.4%12.9%
3 Year-10.2%-10.2%73.5%69.0%39.6%30.2%
5 Year6.0%6.0%158.1%138.5%93.4%71.7%

Price Volatility Vs. Market

How volatile is NuVasive's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NuVasive undervalued compared to its fair value and its price relative to the market?

41.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NUVA ($49.5) is trading below our estimate of fair value ($84.47)

Significantly Below Fair Value: NUVA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NUVA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: NUVA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NUVA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NUVA is good value based on its PB Ratio (2.8x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is NuVasive forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?

64.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NUVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: NUVA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NUVA's is expected to become profitable in the next 3 years.

Revenue vs Market: NUVA's revenue (9% per year) is forecast to grow slower than the US market (9.8% per year).

High Growth Revenue: NUVA's revenue (9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NUVA's Return on Equity is forecast to be low in 3 years time (15.1%).


Next Steps

Past Performance

How has NuVasive performed over the past 5 years?

-6.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NUVA is currently unprofitable.

Growing Profit Margin: NUVA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NUVA is unprofitable, and losses have increased over the past 5 years at a rate of 6.4% per year.

Accelerating Growth: Unable to compare NUVA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NUVA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: NUVA has a negative Return on Equity (-0.43%), as it is currently unprofitable.


Next Steps

Financial Health

How is NuVasive's financial position?


Financial Position Analysis

Short Term Liabilities: NUVA's short term assets ($1.5B) exceed its short term liabilities ($793.4M).

Long Term Liabilities: NUVA's short term assets ($1.5B) exceed its long term liabilities ($961.6M).


Debt to Equity History and Analysis

Debt Level: NUVA's debt to equity ratio (154.3%) is considered high.

Reducing Debt: NUVA's debt to equity ratio has increased from 54.5% to 154.3% over the past 5 years.

Debt Coverage: NUVA's debt is not well covered by operating cash flow (12.7%).

Interest Coverage: NUVA is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is NuVasive current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NUVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NUVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NUVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NUVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NUVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Chris Barry (47 yo)

1.83yrs

Tenure

US$5,425,435

Compensation

Mr. J. Christopher Barry, also known as Chris, serves as Chief Executive Officer and Director of NuVasive, Inc., since November 5, 218. Mr. Barry served commercial and leadership roles at Covidien. He has ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD5.43M) is about average for companies of similar size in the US market ($USD5.63M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
J. Barry
CEO & Director1.83yrsUS$5.43m0.019%
$ 488.6k
Matthew Link
President1.67yrsUS$2.27m0.16%
$ 4.1m
Nathaniel Sisitsky
Senior VP2.67yrsUS$1.14m0.021%
$ 529.7k
Matthew Harbaugh
Executive VP & CFO0.67yrno datano data
Dale Wolf
Senior Vice President of Global Operations0.75yrno datano data
Johnson Lai
Chief Information Officer5.08yrsno datano data
Suzanne Hatcher
Vice President of Internal & External Affairsno datano datano data
Sean Freeman
Senior Vice President of Strategy & Corporate Development0.75yrno datano data
Lucas Vitale
Chief Human Resources Officer1.67yrsno data0.015%
$ 369.1k
Frank Middeke
Managing Director of DACH6.75yrsno datano data
Lisa Pecora
Vice President & Head of Global Commercial Finance2.25yrsno datano data
James Garrett
Senior Vice President of Government & Regulations Strategy0.75yrno datano data

1.7yrs

Average Tenure

45.5yo

Average Age

Experienced Management: NUVA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
J. Barry
CEO & Director1.83yrsUS$5.43m0.019%
$ 488.6k
John DeFord
Independent Director2.58yrsUS$230.06k0%
$ 0
Robert Friel
Independent Director4.58yrsUS$230.06k0%
$ 0
Vickie Capps
Independent Director5.25yrsUS$250.06k0%
$ 0
Gregory Lucier
Chairman of the Board5.5yrsUS$830.06k0.43%
$ 11.0m
R. Huennekens
Independent Director1.92yrsUS$230.06k0.0027%
$ 67.2k
Daniel Wolterman
Independent Director5.17yrsUS$250.06k0%
$ 0
Donald Rosenberg
Independent Lead Director2.33yrsUS$255.06k0.018%
$ 455.1k
Leslie Norwalk
Independent Director6.33yrsUS$240.06k0%
$ 0

4.6yrs

Average Tenure

58yo

Average Age

Experienced Board: NUVA's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

NuVasive, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NuVasive, Inc.
  • Ticker: NUVA
  • Exchange: NasdaqGS
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$2.537b
  • Shares outstanding: 51.25m
  • Website: https://www.nuvasive.com

Number of Employees


Location

  • NuVasive, Inc.
  • 7475 Lusk Boulevard
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NUVANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2004
NK8DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2004
NUVA *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMay 2004

Biography

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine f ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/22 05:31
End of Day Share Price2020/09/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.